This “TTHX 1114 Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about TTHX 1114 for Fuchs Endothelial Corneal Dystrophy (FECD) in the seven major markets. A detailed picture of the TTHX 1114 for FECD in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the TTHX 1114 for FECD. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the TTHX 1114 market forecast analysis for FECD in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in FECD.
Native FGF-1 is a potent stimulator of cell proliferation and migration and has cell-protective properties. It activates all seven forms of the FGF receptor, contributing to its potency. Although FGF-1's activities have been well known, the naturally occurring molecule has an extremely short half-life, rendering it unsuitable for pharmaceutical use (Trefoil Therapeutics, 2021a).
In Trefoil's first development program, TTHX 1114 is being developed as an intracameral injection into the anterior chamber of the eye to potentially offer the first pharmacologic treatment for the back of the cornea surface disease (endothelial dystrophy), FECD, and other corneal endothelial dystrophies, the leading causes of cornea transplantation. It aims to regenerate corneal endothelial cells lost due to the disease, thereby improving vision. It is also developing the topical formulation of the product for ulcerative conditions on the front surface of the cornea, which leads to corneal scarring and substantial loss of vision.
Trefoil has received extensive in-kind development support for TTHX1114's use from the NIH through its Therapeutics for Rare and Neglected Diseases Program.
This product will be delivered within 2 business days.
Drug Summary
TTHX 1114, developed by Trefoil Therapeutics, is a proprietary engineered fibroblast growth factor-1 [FGF-1 (eFGF-1)] variant designed to protect corneal endothelial cells from stress and injury and restore vision loss by stimulating cell proliferation and migration.Native FGF-1 is a potent stimulator of cell proliferation and migration and has cell-protective properties. It activates all seven forms of the FGF receptor, contributing to its potency. Although FGF-1's activities have been well known, the naturally occurring molecule has an extremely short half-life, rendering it unsuitable for pharmaceutical use (Trefoil Therapeutics, 2021a).
In Trefoil's first development program, TTHX 1114 is being developed as an intracameral injection into the anterior chamber of the eye to potentially offer the first pharmacologic treatment for the back of the cornea surface disease (endothelial dystrophy), FECD, and other corneal endothelial dystrophies, the leading causes of cornea transplantation. It aims to regenerate corneal endothelial cells lost due to the disease, thereby improving vision. It is also developing the topical formulation of the product for ulcerative conditions on the front surface of the cornea, which leads to corneal scarring and substantial loss of vision.
Trefoil has received extensive in-kind development support for TTHX1114's use from the NIH through its Therapeutics for Rare and Neglected Diseases Program.
Scope of the Report
The report provides insights into:
- A comprehensive product overview including the TTHX 1114 description, mechanism of action, dosage and administration, research and development activities in Fuchs Endothelial Corneal Dystrophy (FECD).
- Elaborated details on TTHX 1114 regulatory milestones and other development activities have been provided in this report.
- The report also highlights the TTHX 1114 research and development activities in FECD across the United States, Europe and Japan.
- The report also covers the patents information with expiry timeline around TTHX 1114.
- The report contains forecasted sales of TTHX 1114 for FECD till 2032.
- Comprehensive coverage of the late-stage emerging therapies for FECD.
- The report also features the SWOT analysis with analyst views for TTHX 1114 in FECD.
Methodology
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.TTHX 1114 Analytical Perspective
In-depth TTHX 1114 Market Assessment
This report provides a detailed market assessment of TTHX 1114 for Fuchs Endothelial Corneal Dystrophy (FECD) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.TTHX 1114 Clinical Assessment
The report provides the clinical trials information of TTHX 1114 for FECD covering trial interventions, trial conditions, trial status, start and completion dates.Report Highlights
- In the coming years, the market scenario for Fuchs Endothelial Corneal Dystrophy (FECD) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence TTHX 1114 dominance.
- Other emerging products for FECD are expected to give tough market competition to TTHX 1114 and launch of late-stage emerging therapies in the near future will significantly impact the market.
- A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of TTHX 1114 in FECD.
- This in-depth analysis of the forecasted sales data of TTHX 1114 from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the TTHX 1114 in FECD.
Key Questions
- What is the product type, route of administration and mechanism of action of TTHX 1114?
- What is the clinical trial status of the study related to TTHX 1114 in Fuchs Endothelial Corneal Dystrophy (FECD) and study completion date?
- What are the key collaborations, mergers and acquisitions, licensing and other activities related to the TTHX 1114 development?
- What are the key designations that have been granted to TTHX 1114 for FECD?
- What is the forecasted market scenario of TTHX 1114 for FECD?
- What are the forecasted sales of TTHX 1114 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
- What are the other emerging products available and how are these giving competition to TTHX 1114 for FECD?
- Which are the late-stage emerging therapies under development for the treatment of FECD?
This product will be delivered within 2 business days.
Table of Contents
1. Report Introduction3. Competitive Landscape (Marketed Therapies)4. Competitive Landscape (Late-stage Emerging Therapies)6. SWOT Analysis7. Analysts’ Views9. Publisher Capabilities10. Disclaimer11. About the Publisher12. Report Purchase Options
2. TTHX 1114 Overview in FECD
5. TTHX 1114 Market Assessment
8. Appendix
List of Tables
List of Figures
